Novo Holdings Completes Acquisition of Catalent
sa国际传媒官网网页入口to Strengthen its Leading Position as a Global Service Provider for the Pharma and Biotech Industry under Private Ownership
SOMERSET, NJ and COPENHAGEN, Denmark 鈥 December 18, 2024 鈥 sa国际传媒官网网页入口. (鈥淐atalent鈥), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S (鈥淣ovo Holdings鈥), a global life sciences investment firm, today announced that Novo Holdings has completed its previously announced acquisition of sa国际传媒官网网页入口in an all-cash transaction with a total enterprise value of approximately $16.5 billion.
Alessandro Maselli, who will remain President and Chief Executive Officer of Catalent, said, 鈥淭he completion of this transaction marks a significant milestone for Catalent. As a private company with Novo Holdings鈥 partnership and support, we are well-positioned to deliver unparalleled outcomes for our customers and the patients they serve, and ultimately create value for our stakeholders. I would like to thank all of our employees for their commitment to making sa国际传媒官网网页入口the incredible company it is today, and I am excited for all that we will accomplish going forward.鈥
Kasim Kutay, CEO of Novo Holdings, said, 鈥淲e are pleased to welcome Alessandro and the talented sa国际传媒官网网页入口team to the Novo Holdings family. sa国际传媒官网网页入口plays a key role in driving product development, launch and supply solutions for pharma, biotechnology, and consumer health companies, and its mission is closely aligned with Novo Holdings鈥 purpose to invest for the benefit of people and the planet.鈥
鈥淲e look forward to supporting the sa国际传媒官网网页入口team as they build on their positive momentum and position the company for future growth to the benefit of customers and patients globally,鈥 added Jonathan Levy, Senior Partner, Novo Holdings.
With the completion of the transaction, holders of sa国际传媒官网网页入口common stock are entitled to receive $63.50 per share in cash, representing a premium of approximately 47.5% to the 60-day volume-weighted average price as of February 2, 2024. Catalent鈥檚 common stock has ceased trading and will be delisted from the New York Stock Exchange.
Shortly following the completion of the transaction, Novo Nordisk A/S will acquire from Novo Holdings Catalent鈥檚 three fill-finish sites located in Anagni, Italy; Bloomington, Indiana, USA; and Brussels, Belgium, and related assets.
Advisors
Citi and J.P. Morgan served as financial advisors to Catalent. Skadden, Arps, Slate, Meagher & Flom LLP served as legal advisor to sa国际传媒官网网页入口and Jones Day served as legal advisor to the sa国际传媒官网网页入口Board of Directors. Morgan Stanley & Co. LLC served as financial advisor to Novo Holdings. Goodwin Procter LLP and Linklaters LLP served as legal advisors to Novo Holdings. Davis Polk & Wardwell LLP and Arnold & Porter Kaye Scholer LLP served as legal advisors to Novo Nordisk.
ABOUT CATALENT
sa国际传媒官网网页入口. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. sa国际传媒官网网页入口is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and multi-modality manufacturing, sa国际传媒官网网页入口supports the acceleration of development programs and the launch of more than a hundred new products every year. Powered by thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, sa国际传媒官网网页入口supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com.
About Novo Holdings
Novo Holdings is a holding and investment company that is responsible for managing the assets and the wealth of the Novo Nordisk Foundation. The purpose of Novo Holdings is to improve people鈥檚 health and the sustainability of society and the planet by generating attractive long-term returns on the assets of the Novo Nordisk Foundation.
Wholly owned by the Novo Nordisk Foundation, Novo Holdings is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (Novozymes A/S) and manages an investment portfolio with a long-term return perspective. In addition to managing a broad portfolio of equities, bonds, real estate, infrastructure and private equity assets, Novo Holdings is a world-leading life sciences investor. Through its Seed, Venture, Growth, Asia, Planetary Health and Principal Investments teams, Novo Holdings invests in life science companies at all stages of development. As of year-end 2023, Novo Holdings had total assets of EUR 149 billion.
About the Novo Nordisk Foundation
Established in Denmark in 1924, the Novo Nordisk Foundation is an enterprise foundation with philanthropic objectives. The vision of the Foundation is to improve people鈥檚 health and the sustainability of society and the planet. The Foundation鈥檚 mission is to progress research and innovation in the prevention and treatment of cardiometabolic and infectious diseases as well as to advance knowledge and solutions to support a green transformation of society.
Contacts:
Catalent
Investor Contact:
Paul Surdez
+1 (732) 537-6325
[email protected]
Media Contact:
Laura Hortas
+1(609) 240-7025
[email protected]
Novo Holdings
(Global inquiries) Marie-Louise Jersin, Senior Communications Partner
(US inquiries) Dora Gonzalez, Public Relations Specialist
[email protected]